Skip to content

TElemedicine for NARcolepsy

Telemedicine With Mobile Internet Devices for Innovative Multidisciplinary Patient-centred Care of Patients With Narcolepsy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04316286
Acronym
TENAR
Enrollment
202
Registered
2020-03-20
Start date
2020-04-01
Completion date
2023-05-31
Last updated
2023-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Narcolepsy

Brief summary

The TENAR trial is the first randomized controlled trial (RCT) designed to evaluate the feasibility, efficacy, safety, and costs of a Telemedicine multidisciplinary approach for the management of narcolepsy. Open RCT assessing the non-inferiority of the multidisciplinary management of narcolepsy via Video Consultation (VC) through Mobile Telemedicine devices compared to usual in-office care. 202 children and adults with narcolepsy will be randomly allocated in 1:1 ratio to VC or in-office usual care for a 12 months follow-up. At baseline, all patients will undergo a neurologic, metabolic, and psychosocial assessment. Primary (i.e., excessive daytime sleepiness according to the Epworth Sleepiness Scale) and secondary endpoints (i.e., other symptoms, metabolic control, quality of life, patient and family satisfaction with care, feasibility, safety, and costs) will be measured at 6 and 12 months. The investigators expect the Telemedicine approach not only to be non-inferior for sleepiness control but also to significantly improve other patient-centred outcomes compared to the usual in-office care.

Interventions

PROCEDURETele-multidisciplinary care

Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists

OTHERStandard care

Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists

Sponsors

University of Bologna
CollaboratorOTHER
IRCCS Azienda Ospedaliero-Universitaria di Bologna
CollaboratorOTHER
IRCCS Istituto delle Scienze Neurologiche di Bologna
CollaboratorOTHER
Azienda Usl di Bologna
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Adolescents (≥14 years old) and adults with a diagnosis of narcolepsy according to ICSD-3 criteria at their first (incident) or with established diagnosis (prevalent subjects), able to provide consent

Exclusion criteria

* inability to read, write, or using a tablet; * major psychiatric disorders.

Design outcomes

Primary

MeasureTime frameDescription
excessive daytime sleepiness12 monthsMeasured by the Epworth Sleepiness Scale. The Epworth Sleepiness Scale is a self-administered form with eight items investigating sleep propensity in different real-life situations during the preceding months. Each item can received 0-3 points, thus the final score ranges from 0 (best score) to 24 (worse score). The proposed range for normal subjects is 0-10

Secondary

MeasureTime frameDescription
metabolic control - lipid profile Changes12 monthsmetabolic control - lipid profile Changes of: total cholesterol; high-density lipoprotein cholesterol; low-density lipoprotein cholesterol; total triglycerides. All are measured in milligrams per deciliter (mg/dl). \[Time frame: 12 months\]
metabolic control - glycemic profile Changes12 monthsmetabolic control - glycemic profile Changes of fasting glycemia measured in milligrams per deciliter (mg/dl). \[Time frame: 12 months\]
metabolic control - caloric intake Changes12 monthsmetabolic control - caloric intake Changes of caloric intake measured by a food diary. \[Time frame: 12 months\]
metabolic control - physical activity Changes12 monthsmetabolic control - physical activity Changes of physical activity measured by the International Physical Activity Questionnaire (IPAQ). Total physical activity is measured in MET-min/week and time spent sitting, and it is ranked in three levels: low; moderate; high. \[Time frame: 12 months\]
metabolic control - weight Changes12 monthsmetabolic control - weight Changes of weight in kilograms. \[Time frame: 12 months\]
quality of life - Pediatric Quality of Life Inventory12 monthsQuality of life - Pediatric Quality of Life Inventory (PedsQL) Changes of PedsQL health related quality of life (HRQOL) scales. This is a tool of 23 questions comprising four generic domains: physical functioning; emotional functioning; social functioning; school functioning. These domains are measured by a 0-100 scale. Higher scores indicate better HRQOL. \[Time frame: 12 months\]
patient and family satisfaction with care12 monthspatient and family satisfaction with care, measured by an ad-hoc devised form (named Co-Tenar), assessing qualitatively the satisfaction level.
safety12 monthssafety, in terms of number (percent) of full drop-outs, partial drop-outs (patients changing procedure), adverse reactions to drugs in both group of intervention (standard in-office visit arm, video-consultation arm).
costs12 monthscosts related to the disease management (drugs, tests, hospitalization, journeys) will be assessed, by means of a standardized interview, in both group of intervention (standard in-office visit arm, video-consultation arm).
quality of life - Short-Form 36-Item Questionnaire12 monthsQuality of life - Short-Form 36-Item Questionnaire (SF-36) Changes of SF-36 health related quality of life (HRQOL) scales. This tool presents 36 questions. Eight health domains are assessed (physical activities; social activities; limitations in role activities because of physical health problems; bodily pain; mental health; limitations in role activities because of emotional problems; vitality; general health perceptions). Each domain measures a level of HRQOL with a scale between 0-100, with 0 being bad quality of life and 100 being good. \[Time frame: 12 months\]

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026